University of Lethbridge completes dose response study for Gb Sciences’ new Parkinson’s Disease Therapy The study completed at ULethbridge helps pave the way to first-in-human clinical trials
University of Lethbridge chosen to conduct dosage study for novel Parkinson’s disease formulations Dr. Robert Sutherland and his lab will will determine the dose range of active ingredients that will be used in human trials
